Cipla-Eli Lilly partner to distribute Tirzepatide under the Yurpeak brand in India ・Tirzepatide is used to manage type 2 ...

Eli Lilly ( NYSE: LLY) has partnered with India's Cipla to market its weight-loss medication Tirzepatide under a new brand in ...

Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and ...

Mumbai, Oct. 24 -- "The introduction of a second brand of Tirzepatide in India through our commercial agreement with Cipla ...

Indian drugmaker Cipla Limited has entered into a strategic marketing and distribution agreement with US pharma major Eli ...

Indian pharma giant Cipla on Thursday announced an agreement with US pharmaceutical firm Eli Lilly, acquiring the rights to ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

Under the agreement, Cipla will market the drug under a new brand name, Yurpeak, while Lilly continues to sell it as Mounjaro ...

Cipla will market Eli Lilly’s diabetes and weight-loss drug Mounjaro as Yurpeak in India, enhancing accessibility and ...

Eli Lilly (NYSE: LLY) has been one of the best-performing healthcare giants over the past decade. It now stands as the ...

LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity ...

Cipla and Eli Lilly India have announced an agreement to distribute a type 2 diabetes drug, tirzepatide, under the new brand ...